Clinical Trial: Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07079761) titled 'Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.' on June 03.

Brief Summary: Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories prevent them from triggering intensely distressing, disruptive, out-of-place responses.

For examp...